



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/00, 31/55, 31/44 A61K 31/505	A2	(11) International Publication Number: WO 93/23021 (43) International Publication Date: 25 November 1993 (25.11.93)
(21) International Application Number: PCT/GB93/00980 (22) International Filing Date: 13 May 1993 (13.05.93) (30) Priority data: 9210256.5 13 May 1992 (13.05.92) GB 9210270.6 13 May 1992 (13.05.92) GB (71) Applicant (for all designated States except US): THE WELL-COME FOUNDATION LIMITED [GB/GB]; Unicorn House, 160 Euston Road, London NW1 2BP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : LARDER, Brendan, Alexander [GB/GB]; SYMONS, Sharon, Dawn [GB/GB]; Langley Court, Beckenham, Kent BR3 3BS (GB).		(74) Agent: GARRETT, Michael; The Wellcome Foundation Limited, Langley Court, Beckenham, Kent BR3 3BS (GB). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> <i>With a request for rectification under Rule 91(1)(f).</i>
(54) Title: THERAPEUTIC COMBINATIONS (57) Abstract <p>The use of a HIV-RT inhibitor to enhance the sensitivity to zidovudine of zidovudine-resistant HIV populations, the inhibitor being one which induces a mutation at the 181 or 184 position of the RT coding sequence.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

FCI/GB93/00700

"THERAPEUTIC COMBINATIONS"

The present invention relates to therapeutic combinations for the treatment of Human Immunodeficiency Virus (HIV) infections comprising zidovudine and an agent serving to enhance the antiviral activity of zidovudine against HIV populations otherwise resistant to attack by zidovudine.

Zidovudine, which has the chemical name 3'-azido-3'-deoxythymidine, is now well established as an important and useful chemotherapeutic agent for the treatment or prophylaxis of HIV-infections including related clinical conditions such as Acquired Immune Deficiency Syndrome (AIDS), AIDS-related complex (ARC) and also for the treatment of patients who have an asymptomatic HIV infection or who are anti-HIV antibody-positive.

Following the widespread clinical use of zidovudine in the therapy of such infections and conditions, it has been observed that in certain instances following prolonged treatment, the virus may develop a certain level of resistance to zidovudine and therefore a loss of sensitivity to the drug.

Other anti-HIV chemotherapeutic agents have been proposed and investigated, though very few of these agents have the combination of efficacy and safety possessed by zidovudine. Among these agents are various classes of non-nucleoside inhibitors of HIV reverse transcriptase which have been found to have potent anti-HIV activity in vitro. In contrast to nucleoside inhibitors these compounds do not need to be phosphorylated in vivo to exert their inhibitory effect but it has been found that their use rapidly induces resistance by the virus, i.e. loss of antiviral sensitivity to the compound by the virus. Other agents include antiviral nucleoside analogues containing an oxathiolane residue in place of the sugar residue for example nucleosides as described in European Patent Specification No. 382526 particularly (-)-2',3'-dideoxy-3'-thiacytidine, otherwise known as 3TC or lamivudine, and PCT Patent Specification No. WO 92/14743 particularly (-)-2'3'-dideoxy-5-fluoro-3'-thiacytidine otherwise known as FTC. These compounds may be prepared as described in the above relevant Patent Specification.

We have now discovered a solution to the problem encountered in anti-HIV therapy of the development of resistance to zidovudine by the virus. In particular, we have found

that the development and maintenance of resistance by HIV populations can be reduced or prevented, i.e. the sensitivity of such populations to zidovudine can be enhanced, by treating the virus population with an inhibitor of HIV-reverse transcriptase (HIV-RT) which induces a mutation in the RT coding sequence (a) in which the tyrosine residue at position 181 is replaced by a cysteine residue; or (b) in which the methionine residue at position 184 is replaced by a valine or isoleucine residue; such an inhibitor will be referred to hereinafter as "a mutation-inducing HIV-RT inhibitor".

Examples of an HIV-RT inhibitor inducing a mutation of type (a) above include non-phosphorylated HIV-RT inhibitors, ie. inhibitors which are not required to be phosphorylated in vivo to be able to effect inhibition of HIV-RT.

Examples of an HIV-RT inhibitor inducing a mutation of type (b) above include oxathiolane nucleosides of the above types.

According to the present invention therefore we provide:

- (a) a mutation-inducing HIV-RT inhibitor for use in enhancing or maintaining the antiviral sensitivity of an HIV population to zidovudine or a physiologically functional derivative thereof;
- (b) a therapeutic combination for the treatment or prophylaxis of HIV infections, especially zidovudine-resistant HIV infections, which comprises zidovudine or a physiologically functional derivative thereof, and a mutation-inducing HIV-RT inhibitor, whereby the antiviral sensitivity of a HIV population to zidovudine is enhanced or maintained by the said inhibitor;
- (c) a method of enhancing or maintaining the antiviral sensitivity of an HIV population to zidovudine or a physiologically functional derivative thereof which comprises contacting said population with an effective amount of a mutation-inducing HIV-RT inhibitor;
- (d) a method of treating a subject (e.g. a human) having an HIV infection resistant to zidovudine which comprises administering to the subject a combination of zidovudine or a physiologically functional derivative thereof and a mutation-

inducing HIV-RT inhibitor;

- (e) a mutation-inducing HIV-RT inhibitor for use in HIV therapy against HIV infections which are resistant to zidovudine;
- (f) a method of increasing the sensitivity of a HIV population resistant to zidovudine or a physiologically functional derivative thereof comprising treating the virus with a mutation-inducing HIV-RT inhibitor.

It will be appreciated that the enhancement or maintenance of sensitivity to zidovudine of an HIV population in a patient can be readily determined in conventional manner, for example by observation of the relative clinical efficacy of the drug and/or by analytical determination of the levels of the virus or markers thereof in samples of appropriate biological materials (e.g. plasma) from the patient and/or by the determination of antiviral sensitivity in vitro in cell cultures of virus obtained from patients.

We have carried out in vitro experiments in which an HIV-1 population containing four mutations in the HIV-RT which confer zidovudine resistance was exposed in cell culture to increasing concentrations of a non-phosphorylated HIV-RT inhibitor represented by the compound known as "Chloro-TIBO", i.e. 9-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-S-imidazo[4,5,i-jk][1,4]benzodiazepine-2(1H)-thione. The virus became gradually more resistant to Chloro-TIBO and after five passages the 50% inhibitory concentration (IC_{50}) for the compound against the virus had increased by more than fifty-fold, i.e. antiviral sensitivity to Chloro-TIBO had decreased. In contrast the sensitivity of the virus population to zidovudine had simultaneously increased about twenty fold, the IC_{50} value for zidovudine decreasing from about 2 μ M to less than 0.1 μ M. It has been discovered through similar in vitro passage experiments that HIV can acquire rapid resistance to oxathialane nucleosides such as FTC and 3TC. Thus, the introduction of the M184 to V mutation into a zidovudine-resistant HIV strain (HIVRTMC), resulted in an increase in resistance to FTC (IC_{50} values increased from 0.64 μ M to >500 μ M), whereas the virus became less resistant to zidovudine (IC_{50} values fell from 1.26 μ M to 0.17 μ M). When the resistance mutation, Y181 to C, together with M184 to V, were introduced into this zidovudine-resistant virus, there was an even more pronounced effect on the enhancement of zidovudine sensitivity. The resulting mutant virus strain was now co-

resistant to the oxathialane nucleosides and non-phosphorylated HIV-RT inhibitors, but had become completely sensitive to zidovudine (IC_{50} values for zidovudine fell from 1.26 to 0.04).

In accordance with the present invention, a mutation-inducing HIV-RT inhibitor may be used to enhance the antiviral sensitivity of a zidovudine-resistant HIV population to zidovudine or alternatively to maintain the antiviral sensitivity of a HIV population in which zidovudine-resistance has not been induced.

Examples of non-phosphorylated HIV-RT inhibitors which may be employed in conjunction with the invention include:-

- a) tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-ones and -thiones (the so-called "TIBO" derivatives) for example as described by Pauwels *et al* (1990) *Nature*, 343, 470-474, and in European Patent Specification No. 384522.

A particularly preferred TIBO derivative for use in accordance with the invention is "Chloro-TIBO" (R-82913) referred to above.

- b) dipyrindodiazepinones for example as described by Merluzzi *et al* (1990) *Science*, 250, 1411-1413 and in European Patent Specification No. 429987.

A particular example of this class of compounds is the compound known as nevirapine (BI-RG-587), i.e. 11-cyclopropyl-5-,11-dihydro-4-methyl-6H-dipyrido[3,2-6:2',3'-e][1,4]diazepin-6-one.

- c) pyridinones (the so-called "L-drugs") for example as described by Goldman *et al* (1991) *Proc. Nat. Acad. Sci.*, 88, 6863-6867 and in European Patent Specification No. 462800.

A particular example of this class of compounds is L-697,639, i.e. 3-[[[(4,7-dimethyl-2-benzoxazolyl)methyl]amino]-6-ethyl-6-methyl-2(1H)pyridinone.

- d) bis(heteroaryl)piperazines (the so-called "BHAPS") as described for example by Romero *et al* (1991) *Proc. Nat. Acad. Sci.*, 8806-8810 and in International Patent

Specification No. WO 91/09849.

A particular example of this class of compounds is U-87201, namely 1-[3-(ethylamino)-2-pyridinyl]-4-[(5-methoxy-1H-indol-2-yl)carbonyl]-piperazine.

- e) 5-ethyl-6-(phenylthio)uracil derivatives (the so-called "HEPT compounds") as described for example by Baba *et al*, Proc. Nat. Acad. Sci, (1991) 88, 2356-2360 and in European Patent Specification No. 420763.
- f) quinazoline derivatives for example as described in European Patent Specification No. 530994.
- g) anilinophenylacetamide derivatives for example as described in Proc. Natl. Acad. Sci. Vol 90, 1711-15, 1993

As an alternative to the non-phosphorylated HIV-RT inhibitor employed in accordance with the invention as described above, it is possible to use a HIV-RT inhibitor which induces a mutation in the RT coding sequence in which a methionine residue at position 184 is replaced by a valine or isoleucine residue (a "184 mutation HIV-RT inhibitor"). Such HIV-RT inhibitors may therefore be used in place of, or in addition to, the non-phosphorylated HIV-RT inhibitor as previously described. Examples of the 184 mutation HIV-RT inhibitors include antiviral nucleoside analogues containing an oxathiolane residue in place of the sugar residue for example nucleosides as described in European Patent Specification No. 382526 particularly (-)-2',3'-dideoxy-3'-thiacytidine, otherwise known as 3TC or lamivudine, and PCT Patent Specification No. WO 92/14743 particularly (-)-2'3'-dideoxy-5-fluoro-3'-thiacytidine otherwise known as FTC. These compounds may be prepared as described in the above relevant Patent Specification.

An especially preferred embodiment of the present invention comprises the use of a non-phosphorylated HIV-RT inhibitor and a 184 mutation HIV-RT inhibitor such as lamivudine or FTC together with zidovudine. The use in combination of the two types of HIV-RT inhibitor results in a very significant effect in reducing or preventing the development and maintenance by HIV populations of resistance to zidovudine.

By "physiologically functional derivative" of zidovudine is meant a pharmaceutically acceptable salt, ester or salt of an ester of zidovudine, or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) zidovudine or an active metabolite or residue thereof.

Preferred esters according to the invention include carboxylic acid esters in which the non-carbonyl moiety of the ester grouping is selected from straight or branched chain alkyl e.g. n-propyl, t-butyl, n-butyl, alkoxyalkyl (e.g. methoxymethyl), aralkyl (e.g. benzyl), aryloxyalkyl (e.g. phenoxymethyl), and aryl (e.g. phenyl); sulfonate esters such as alkyl- or aralkylsulfonyl (e.g. methanesulfonyl); amino acid esters (e.g. L-valyl or L-isoleucyl); dicarboxylic acid esters (e.g., hemisuccinate); and mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C₁₋₂₀ alcohol or reactive derivative thereof, or by a 2,3-di(C₆₋₂₄)acyl glycerol.

Any alkyl moiety present in such esters advantageously contains 1 to 18 carbon atoms, particularly 1 to 4 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group optionally substituted, e.g. by halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or nitro.

Examples of pharmaceutically acceptable salts include base salts, e.g. derived from an appropriate base, such as alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium) salts, ammonium and NX_4^+ (wherein X is C₁₋₄ alkyl). Pharmaceutically acceptable acid addition salts include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.

Examples of viral infections and associated clinical conditions which may be treated or prevented in accordance with the invention, include human retroviral infections such as HIV, e.g. HIV-1 or HIV-2, and human T-cell lymphotropic virus (HTLV), e.g. HTLV-I or HTLV-II infections. The combinations of the present invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS-related complex (ARC), progressive generalized lymphadenopathy (PGL), AIDS-related neurological conditions, such as multiple sclerosis or tropical paraparesis, anti-HIV antibody-positive and HIV-positive conditions such as thrombocytopenic purpura. The combinations of

the present invention may also be used in the treatment of psoriasis. The combinations of the present invention have been found to be particularly applicable to the treatment of asymptomatic infections or diseases caused by or associated with HIV.

It will be appreciated that in accordance with the present invention the components of the combinations may be administered simultaneously, concurrently or sequentially. In the latter case, however, the components are administered within a sufficiently short interval to ensure that an enhancement of the antiviral sensitivity of an HIV population to zidovudine is achieved.

An advantage of the combinations of the present invention is that it enables one to treat subjects having a zidovudine-resistant HIV infection who would otherwise be precluded from such treatment with the drug.

Zidovudine and/or the mutation-inducing HIV-RT inhibitor may employed in accordance with the invention together with other therapeutic agents for the treatment of the above infections or conditions. Examples of such further therapeutic agents include agents that are effective for the treatment of HIV infections or associated conditions, such as 2',3'-dideoxynucleosides, e.g. 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine, carbovir, 2',3'-didehydrothymidine, acyclic nucleosides (for example, acyclovir), protease inhibitors, such as RO 31-8959, oxathiolan nucleoside analogues, such as, cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (3TC), interferons, such as α -interferon, renal excretion inhibitors, such as probenecid, nucleoside transport inhibitors, such as dipyridamole, as well as immunomodulators, such as interleukin II, granulocyte macrophage colony stimulating factors, and erythropoetin, phosphonoformic acid, soluble CD₄ and genetically engineered derivatives thereof. The component compounds of such combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times, for example sequentially, such that a combined effect is achieved.

The compounds employed in accordance with the present invention may be administered to a mammal in a conventional manner. As indicated above, the components of the above combinations may be administered simultaneously (e.g., in a unitary pharmaceutical formulation) or separately (e.g., in separate pharmaceutical

formulations). In general, the combinations may be administered by the topical, oral, rectal or parenteral (e.g., intravenous, subcutaneous or intramuscular) routes. It will be appreciated that the route may vary with, for example, the severity of the condition to be treated and the identity of the recipient.

Thus the optimum molar ratio of the zidovudine (or a physiologically functional derivative thereof) to the mutation-inducing HIV-RT inhibitor for use according to this invention is from 10:1 to 1:10, preferably from 1:1 to 1:5, and most preferably 1:3.

Hereafter the components of the combination may be referred to as "active ingredients".

The dosages of the compounds will depend on the condition being treated and other clinical factors such as the weight and condition of the recipient and the route of administration of the components of the combinations. Examples of dose ranges and component ratios are as follows:

In general a suitable dose of zidovudine (or a physiologically functional derivative thereof) will be in the range of 3 to 120 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg per kilogram body weight per day and most preferably in the range 10 to 30 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dose forms, for example, containing a total of 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredients per unit dose form.

With regard to the non-phosphorylated HIV-RT inhibitor, the dosage will vary depending on the particular inhibitor employed in addition to the other factors referred to above. However, in general, a daily dosage of 0.1 to 100 mg/kg for example 1 to 50 mg/kg may be employed. Preferred daily dosages for the specific compounds or groups of compounds preferred to above are 0.1 to 20, preferably 0.1 to 5 mg/kg for Chloro-TIBO, 0.5 mg to 1 g /day for nevirapine, 1 to 20 mg/kg for L-697,639, 0.1 to 500 mg/kg for U-87201 and 1 to 100, preferably 5 to 50 mg/kg for the HEPT compounds.

With regard to the above 184 mutation HIV-RT inhibitors such as the antiviral

oxathiolane nucleosides, daily doses for the compounds described in European Patent Specification No. 382526 include 1 to 750mg/kg, preferably 3 to 120mg/kg especially 6 to 90mg/kg. Daily doses for the compounds described in PCT Patent Specification No. WO 92/14743 include 0.1 to 100mg/kg, preferably 1 to 50mg/kg especially 1 to 20mg/kg.

While it is possible for the active ingredients to be administered alone it is preferable to present them as pharmaceutical formulations. Pharmaceutical formulations of the present invention comprise a combination according to the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. When the individual components of the combination are administered separately they are generally each presented as a pharmaceutical formulation. The references hereinafter to formulations refer unless otherwise stated to formulations containing either the combination or a component thereof. Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredients with the carrier which constitutes one or more accessory ingredients.

In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or

granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Topical administration may also be by means of a transdermal iontophoretic device.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents; and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of

the kind previously described.

Preferred unit dosage formulations are those containing a daily dose or daily subdose of the active ingredients, as hereinbefore recited, or an appropriate fraction thereof.

It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.

The compounds of the combination of the present invention may be obtained in conventional manner. Zidovudine can be prepared, for example, as described in U.S. Patent 4724232, incorporated herein by reference. Zidovudine can also be obtained from Aldrich Chemical Co., Milwaukee, WI 53233, USA.

The mutation-inducing HIV-RT inhibitors can be prepared in accordance with the processes described in the above-references relating to such inhibitors.

The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way. "Active ingredient" denotes zidovudine and/or a non-phosphorylated HIV-RT inhibitor.

Example 1: Tablet Formulation

The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

Formulation A

	<u>mg/tablet</u>
Active Ingredient	250
Lactose B.P.	210
Povidone B.P.	15
Sodium Starch Glycollate	20
Magnesium Stearate	5
	<hr/>
	500

Formulation B

	<u>mg/tablet</u>
Active Ingredient	250
Lactose B.P.	150
Avicel PH 101	60
Povidone B.P.	15
Sodium Starch Glycollate	20
Magnesium Stearate	5
	<hr/>
	500

Formulation C

	<u>mg/tablet</u>
Active Ingredient	250
Lactose B.P.	200
Starch	50
Povidone	5
Magnesium Stearate	4
	<hr/>
	359

The following formulations, D and E, are prepared by direct compression of the

admixed ingredients. The lactose in formulation E is of the direct compression type (Dairy Crest - "Zeparox").

Formulation D

	<u>mg/tablet</u>
Active Ingredient	250
Pregelatinized Starch NF15	150
	<hr/>
	400

Formulation E

	<u>mg/tablet</u>
Active Ingredient	250
Lactose B.P.	150
Avicel	100
	<hr/>
	500

Formulation F (Controlled Release Formulation)

The formulation is prepared by wet granulation of the ingredients with a solution of povidone followed by the addition of magnesium stearate and compression.

	<u>mg/tablet</u>
Active Ingredient	500
Hydroxypropylmethylcellulose (Methocel K4M Premium)	112
Lactose B.P.	53
Povidone B.P.	28
Magnesium Stearate	7
	<hr/>
	700

Drug release takes place over a period of about 6-8 hours and is complete after 12 hours.

Example 2: Capsule Formulations

Formulation A

A capsule formulation is prepared by admixing the ingredients of formulation D in Example 1 above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner.

Formulation B

	<u>mg/capsule</u>
Active Ingredient	250
Lactose B.P.	143
Sodium Starch Glycollate	25
Magnesium Stearate	2
	<hr/>
	420

Formulation C

	<u>mg/capsule</u>
Active Ingredient	250
Macrogel 4000 B.P.	350
	<hr/>
	600

Capsules of formulation C are prepared by melting the Macrogel 4000 B.P., dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.

Formulation D

	<u>mg/capsule</u>
Active Ingredient	250
Lecithin	100
Arachis Oil	100
	<hr/>
	450

Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

Formulation E (Controlled Release Capsule)

The following controlled release capsule formulation is prepared by extruding ingredients a, b, and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

	<u>mg/capsule</u>
(a) Active Ingredient	250
(b) Microcrystalline Cellulose	125
(c) Lactose B.P.	125
(d) Ethyl Cellulose	13
	<hr/>
	513

Example 3: Injectable FormulationFormulation A

	<u>mg</u>
Active Ingredient	200
Hydrochloric Acid Solution 0.1 M <u>or</u>	
Sodium Hydroxide Solution 0.1 M q.s. to pH	4.0 to 7.0
Sterile water q.s. to	10 ml

The active ingredient is dissolved in most of the water (35°-40°C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10 ml amber glass vial (type 1) and sealed with sterile closures and overseals.

Formulation B

Active Ingredient	125 mg
Sterile, Pyrogen-free, pH 7 Phosphate	
Buffer, q. s. to	25 ml

Example 4: Intramuscular injection

Active Ingredient	200 mg
Benzyl Alcohol	0.10 g
Glycofurol 75	1.45 g
Water for injection q.s. to	3.00 ml

The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1).

Example 5: Syrup

Active Ingredient	250 mg
Sorbitol Solution	1.50 g
Glycerol	2.00 g
Sodium Benzoate	0.005 g
Flavor, Peach 17.42.3169	0.0125 ml
Purified Water q.s. to	5.00 ml

The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbital solution and finally the flavor. The volume is made up with purified water and mixed well.

Example 6: Suppository

mg/capsule suppository

Active Ingredient	250
Hard Fat, B.P. (Witepsol H15 - Dynamit Nobel)	1770
	<hr/>
	2020

One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200µm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250µm stainless steel screen and, with continuous stirring, is allowed to cool to 40°C. At a temperature of 38°C to 40°C, 2.02 g of the mixture is filled into suitable, 2 ml plastic molds. The suppositories are allowed to cool to room temperature.

Example 7: Pessaries

	<u>mg/pessary</u>
Active Ingredient	250
Anhydrate Dextrose	380
Potato Starch	363
Magnesium Stearate	<u>7</u>
	1000

The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.

CLAIMS

1. A mutation-inducing inhibitor of Human Immunodeficiency Virus reverse transcriptase (HIV-RT) which induces a mutation in the RT coding sequence (a) in which the tyrosine residue at position 181 is replaced by a cysteine residue; or (b) in which the methionine residue at position 184 is replaced by a valine or isoleucine residue, for use in enhancing or maintaining the antiviral sensitivity of an HIV population to zidovudine or a physiologically functional derivative thereof;
2. An inhibitor of HIV-RT as claimed in claim 1 which induces a mutation in the RT coding sequence in which the tyrosine residue at position 181 is replaced by a cysteine residue.
3. An inhibitor of HIV-RT as claimed in claim 2 which is an inhibitor which is not required to be phosphorylated in vivo to be able to effect inhibition of HIV-RT.
4. An inhibitor of HIV-RT as claimed in claim 3 selected from the following classes of such inhibitors, namely:-

tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-ones and -thiones; dipyrrodo-diazepinones; pyridinones; bis(heteroaryl)piperazines; and 5-ethyl-6-(phenylthio)uracil derivatives.
5. An inhibitor of HIV-RT as claimed in claim 1 which induces a mutation in RT coding sequence in which the methionine residue at position 184 is replaced by a valine or isoleucine residue.
6. An inhibitor of HIV-RT as claimed in claim 5 which is an antiviral oxathiolane nucleoside.
7. An inhibitor of HIV-RT as claimed in claim 6 selected from (-)-2',3'-dideoxythiacytidine and (-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine.

8. A combination of two mutation-inducing inhibitors as claimed in claim 1, one such inhibitor being as defined in claim 2 and the other being as defined in claim 5.
9. A therapeutic combination for the treatment or prophylaxis of HIV infections which comprises zidovudine or a physiologically functional derivative thereof, and a mutation-inducing HIV-RT inhibitor (as defined in claim 1), whereby the antiviral sensitivity of a HIV population to zidovudine is enhanced or maintained by the said inhibitor.
10. A combination as claimed in claim 9 in which the mutation-inducing HIV-RT inhibitor is as defined in any of claims 2 to 7.
11. A combination as claimed in claim 9 or claim 10 for the treatment of HIV infections.
12. A method of enhancing the antiviral sensitivity of an HIV population to zidovudine or a physiologically functional derivative thereof which comprises contacting the population with an effective amount of a Human Immunodeficiency Virus reverse transcriptase (HIV-RT) inhibitor which induces a mutation in the RT coding sequence (a) wherein the tyrosine residue at position 181 of HIV-RT is replaced by a cysteine residue or (b) wherein the methionine residue at position 184 of HIV-RT is replaced by a valine or isoleucine residue.
13. A method of maintaining the antiviral sensitivity of an HIV population to zidovudine or a physiologically functional derivative thereof which comprises contacting the population with an effective amount of an HIV-RT inhibitor which induces a mutation in the RT coding sequence (a) wherein the tyrosine residue at position 181 of HIV-RT is replaced by a cysteine residue or (b) wherein the methionine residue at position 184 of HIV-RT is replaced by a valine or isoleucine residue.

14. A method of treating a subject having an HIV infection resistant to zidovudine which comprises administering to said subject a combination of zidovudine or a physiologically functional derivative thereof and a mutation-inducing HIV-RT inhibitor.
15. A method as claimed in claim 14 in which said subject is a human

The Wellcome Foundation Ltd

The Wellcome Research Laboratories

Langley Court, South Eden Park Road,
Beckenham, Kent BR3 3BS

Wellcome

telegrams and cables
WELLAB BECKENHAM
telex WELLAB 23937 G
fax 081-650 9862
telephone 081-658 2211



Our Ref: WPMJTPA1344 PCT

13th September 1993

WIPO

34 Chemin Des Colombettes
1211 Geneva 20
Switzerland

Reçu chèque	12001
montant	CHF 50.-
date:	- 8 OCT. 1993

Falt *21*
photocopie

Am JENENH

With a request for rectification under Rule 91.1(f).

Dear Sirs

Re: International Patent Application No. PCT/GB93/00980

Our request for correction of the priority claim in the PCT request of the above application has been refused by the UK Patent Office. Could you therefore publish in the PCT publication document that a request for correction of the priority claim will be made again in the national/regional phase (Rule 91(f) PCT). For your information the correct priority number is GB930713.4 (filed 2 April 1993) and the incorrectly claimed number is GP9210270.6 (filed 13 May 1992). Our cheque for 50 Swiss Francs is enclosed for payment of the fee.

Yours sincerely

W P McMunn
W P McMUNN

GROUP PATENTS AND AGREEMENTS